Search results
Panel recommends blood test to detect colon cancer for FDA approval
UPI· 2 days agoA panel of U.S. Food and Drug Administration advisers on Thursday recommended approval for a new...
FDA panel recommends approval of a blood test for colon cancer
NBC NEWS· 2 days agoAdvisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of...
How cannabis and psilocybin might help some of the 50 million Americans who are experiencing chronic...
The Conversation via Yahoo News· 2 hours agoCannabis and psilocybin – used under supervision – have the potential to work better than current...
US FDA staff says Guardant’s test may fail to detect some pre-cancerous tumors
WSAU Wausau· 4 days ago(Reuters) -The U.S. Food and Drug Administration's staff reviewers on Tuesday raised concerns that...
US FDA staff says Guardant's test may fail to detect some pre-cancerous tumors
Reuters via Yahoo News· 4 days agoThe reviewers, however, said the test may increase compliance with screening for colorectal cancer...
Best OTC Hearing Aids | Fortune Recommends Health
Fortune· 3 days agoOur list of the best OTC hearing aids provides options for a variety of users and preferences.
Carnivore diet explained: What it is, benefits and risks
The Telegraph via Yahoo News· 3 days agoVegetables Fruit Nuts and seeds Legumes Grains, including food made from them, such as pasta and...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 1 day agoMycotoxin Testing Market worth $2.3 billion by 2029 - Exclusive Report by MarketsandMarkets™ PR Newswire CHICAGO, May 24, 2024 CHICAGO, May 24, 2024 /PRNewswire/ -- The Mycotoxin Testing Market is estimated at USD 1.6 billion in 2024 and is projected
U.S. FDA advisers back approval for Guardant's blood-based cancer test
Reuters· 2 days ago, opens new tab blood test to detect a cancer that begins in the colon or rectum. The panel voted...
U.S. FDA advisers back approval for Guardant's blood-based cancer test (May 23) By Reuters
Investing.com· 2 days agoThe panel voted seven-to-two in favor of benefits outweighing risks when using the test called...